Volume 89 Issue 2 | p. 19 | Concentrates
Issue Date: January 10, 2011

AMRI Inks Deal With Genentech

Department: Business
Keywords: antibacterial agents, collaboration

Albany Molecular Research Inc. has signed a licensing agreement with Genentech under which the Roche-owned biotech company will receive an exclusive license to develop drug candidates from AMRI’s antibacterial program. AMRI derived the candidates from its natural products sample collection. In addition, AMRI will collaborate with Genentech in a research program to identify novel antibacterial agents. AMRI will receive an undisclosed up-front licensing fee as well as developmental milestone payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment